Anti-N-terminal Arginylation Antibody [4A9]

N-terminal Arginylation Antibody [4A9]

N-terminal Arginylation Antibody [4A9] is a mouse recombinant monoclonal antibody directed against N-terminal Arginylation, offered by Assay Genie for research applications. Reported applications include WB, FCM and FACS. Reactivity is species independent. Supplied as IgG1, purified by Protein G.

N-terminal arginylation is a post-translational modification catalyzed by arginyltransferase ATE1, in which an arginine residue is added to the N-terminus of proteins. This process plays a critical role in protein quality control, cellular stress responses, and neurodevelopment. In the nervous system, N-terminal arginylation regulates the degradation of misfolded or damaged proteins via the N-degron pathway, thereby maintaining proteostasis—a function essential for neuronal survival. Recent studies have linked impaired arginylation to neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where accumulation of misfolded proteins and disrupted stress responses are key pathological features. Arginylation also modulates cytoskeletal dynamics and synaptic plasticity, suggesting broader roles in neuronal connectivity and cognitive function. Dysregulation of ATE1 activity has been associated with increased vulnerability to oxidative stress and endoplasmic reticulum stress, both of which are implicated in neurodegeneration. Given its multifaceted role in neuronal health, N-terminal arginylation represents a promising target for therapeutic intervention and biomarker development in neurodegenerative disease research. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µg. For research use only; not for diagnostic or therapeutic procedures.